Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs Business Wire Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United [...]
ReNew Reports 25.6% Reduction in Scope 1 & 2 Emissions and 24.7 Billion Units of Clean Power Generated in FY 2025-26 Business Wire ReNew Energy Global Plc (“ReNew”) (NASDAQ: RNW), one of the world’s leading decarbonisation solutions companies, announced a 25.6% reduction in Scope 1 & 2 emissions from its FY 2021‑22 baseline, surpassing its FY 2025‑26 target of 23.5%. The Company also generated 24.7 billion units of clean electricity, equivalent to powering ~21.2 million households and avoiding [...]
Interactive Brokers Adds Access to the Bucharest Stock Exchange, Offering Access to One of Europe’s Strongest-Performing Markets of 2025 Business Wire Eligible clients can now trade Romanian stocks on the Bucharest Stock Exchange, alongside products from over 170 global markets, on one platform
Strzala Architects and Corgan to Support Major Capital Investment Programmes for UK’s Manchester Airports Group August 13, 2026 Manchester-based Strzala Architects, with global architecture and design firm Corgan as subconsultant, has been appointed to a consultancy framework established by Manchester Airports Group (MAG) to support capital investment programmes across its airports over the next five years. Strzala Architects has secured a position on the framework under Lot 7: RIBA Stages 1+2 Architecture, partnering [...]
BM3EAC Corp. 2026 Semi-Annual Report August 12, 2026 BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2026 to 30 June 2026. The semi-annual report [...]
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering August 12, 2026 Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United [...]
GXP-Storage Expands UK Capacity with Third Restricted-Access Facility at Raunds, Northamptonshire August 11, 2026 The company’s third UK facility adds 95,000+ cubic feet of GxP-compliant, environmentally controlled storage capacity and serves as a consolidation point for regulated materials across the UK, EMEA, and beyond.
Organigram Reports Record Third Quarter Fiscal 2026 Results August 11, 2026 Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares August 10, 2026 Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET